Nilotinib is a small-molecule tyrosine kinase inhibitor approved for the treatment of imatinib-resistant chronic myelogenous leukemia. it was developed based on the structure of the Abl-imatinib complex to address imatinib intolerance and resistance. Nilotinib is a selective Bcr-Abl kinase inhibitor that is 10-30 fold more potent than imatinib in inhibiting Bcr-Abl tyrosine kinase activity and proliferation of Bcr-Abl expressing cells.

It is approved by FDA- (29 October 2007), EMA- (29 September 2009), MHRA- (19 November 2007) and TGA- (17 January 2008) for use as a treatment for Philadelphia Chromosome (Ph+)-positive Chronic myelogenous leukaemia. on April 11, 2011, Novartis announced that it is discontinuing a Phase III trial of Tasigna® (nilotinib) for investigational use in the first-line treatment of gastrointestinal stromal tumor(GIST) based on the recommendation of an independent data monitoring committee.

We provide the key intermediate (641571-11-1) and API, white to off-white powder,

the purity is more than 99.5%(HPLC).

Top quality, more competitive price.

NMR,HPLC,IR,MOA,COA are available,

Special packing is offered.